A complete joint treatment

I-ONE® therapy

ICEA®
CLINICAL BIOPHYSICS

I-ONE® therapy

A complete joint treatment

I-ONE® THERAPY DELIVERS A SIGNAL PERMEATING THE ENTIRE EXTENSION AND DEPTH OF THE ARTICULAR CARTILAGE AS WELL AS THE ARTICULAR STRUCTURES AND THE SUBCHONDRAL BONE.



Cartilage

I-ONE® therapy stimulates the synthesis of the cartilage matrix and exerts a chondroprotective effect.

Synovia

I-ONE® therapy exerts an anti-inflammatory effect, decreasing the release of catabolic factors (TNF-α, IL-6, IL-8, IL-1β, PGE2) and increasing the production of anabolic factors (IL-10, TGF-β1).

Subchondral bone

I-ONE® therapy prevents the sclerosis of the subchondral bone and facilitates the bone oedema reabsorption.

I-ONE® therapy performs a triple action:

1. **ANTI-INFLAMMATORY ACTION ON THE WHOLE JOINT**
2. **ANABOLIC ACTION ON THE CARTILAGE**
3. **TROPHIC ACTION ON THE SUBCONDRAL BONE**

A modern, innovative and reliable technology

» ACTUAL SIZE IMAGE «

»PORTABLE DEVICE«

Patented

A biophysical signal covered by international patents makes I-ONE® therapy unique and **not reproducible.**

Safety

The therapy parameters are preset by IGEA and cannot be modified by the patient, in compliance with the current legislation. To ensure safety, efficacy and simplicity of use, I-ONE® therapy is **operated with a single button (on/off).**

Compliance

A light, flexible and ergonomic coil guarantees the best possible freedom of movement.

Efficacy

Similarly to a pharmacological therapy, the efficacy of the therapy is guaranteed by a homogeneous and correct distribution of the biophysical signal in the area to be treated.

Sites treatable with I-ONE® therapy



Early Osteoarthritis

I-ONE® therapy is indicated in patients with grade 0-2 osteoarthritis, according to the Kellgren-Lawrence classification, presenting pain and functional limitation.

I-ONE® therapy

- **Exerts a chondroprotective effect.**
- **Controls pain.**
- **Improves joint functionality.**



Gobbi A et al. JST, 2011

Patients treated with I-ONE® therapy showed an improvement in pain, quality of life and a full return to daily activities.
To maintain long-term results from the use of I-ONE® therapy it is advisable to repeat the treatment annually.

Bone Oedema / SONK

I-ONE® therapy is indicated in symptomatic patients with acute or chronic bone oedema of idiopathic, post-traumatic or degenerative origin.

I-ONE® therapy

- **Enhances the process of oedema reabsorption.**
- **Treats pain and improves activity level.**
- **Delays arthroplasty surgery.**

REDUCTION OF **PAIN** IN
75% OF THE PATIENTS
AT 6-MONTH FOLLOW-UP



Marcheggiani Muccioli GM et al. Eur J Radiol, 2013

CLINICAL CASE

BEFORE



I-ONE® therapy

AFTER 3 MONTHS



Courtesy dr Marcheggiani Muccioli (Bologna, Italy)

Algodystrophy

I-ONE® therapy is indicated in patients with Type I algodystrophy or CRPS (Complex Regional Pain Syndrome).

I-ONE® therapy

- **Controls the joint inflammatory process.**
- **Treats pain.**
- **Inhibits osteoclastogenesis.**



I-ONE® therapy **STOPS THE VICIOUS CIRCLE**, acting on inflammation, oedema and pain.

CLINICAL CASE

BEFORE **I-ONE® therapy** **AFTER**

Borelli PP. Chir Mano, Vol. 54(3) 2017

Patellofemoral Pain Syndrome



I-ONE® therapy is indicated in patients with Patellofemoral Pain Syndrome (PFPS) with pain localised in the anterior part of the knee when walking or doing sporting activities.

I-ONE® therapy

- **Treats pain.**
- **Reduces NSAIDs consumption.**
- **Allows a rapid return to sporting activity.**

VISA score variation

RESUMPTION OF SPORTING ACTIVITY



VAS scale variation

PAIN RESOLUTION



Iammarrone Servodio C et al. Bioelectromagnetics, 2015

IGEA®
CLINICAL BIOPHYSICS

Clinical indications

- EARLY OSTEOARTHRITIS
- JOINT INFLAMMATION
- INTRA-ARTICULAR EFFUSION
- BONE OEDEMA / SONK
- PATELLOFEMORAL PAIN SYNDROME
- ALGODYSTROPHY (CRPS)




Daily treatment time: 4 hours. Treatment duration: 30-60 days.
The therapy can be repeated.

References

- Benazzo F et al. Cartilage repair with osteochondral autografts in sheep: effect of biophysical stimulation with pulsed electromagnetic fields. J Orthop Res. 2008 May;26(5):631-42
- Fini M et al. Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs. Biomed Pharmacother. 2008 Dec;62(10):709-15
- Gobbi A et al. L'uso dei campi elettromagnetici pulsati in pazienti sintomatici con lesioni degenerative della cartilagine del ginocchio: un rapporto preliminare. Journal of Sports Traumatology. 2011;Vol. 28, No. 4. Dicembre 2011
- Ongaro A et al. Chondroprotective effects of pulsed electromagnetic fields on human cartilage explants. Bioelectromagnetics. 2011 Oct;32(7):543-51
- Bruscoli R. Necrosi del CFM del ginocchio in un podista master. Trattamento con CEMP. ReaLiMe, Maggio 2012;14:15
- Ongaro A et al. Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. J Cell Physiol. 2012 Jun;227(6):2461-9
- Marcheggiani Muccioli GM et al. Conservative treatment of spontaneous osteonecrosis of the knee in the early stage: Pulsed electromagnetic fields therapy. Eur J Radiol. 2013 Mar;82(3):530-7
- Gobbi A et al. Symptomatic Early Osteoarthritis of the Knee Treated With Pulsed Electromagnetic Fields: Two-Year Follow-up. Cartilage. 2014 Apr ; 5(2) :76-83
- Ongaro A et al. Pulsed electromagnetic fields stimulate osteogenic differentiation in human bone marrow and adipose tissue derived mesenchymal stem cells. Bioelectromagnetics. 2014 Sep;35(6):426-36
- Veronesi F et al. In vivo effect of two different pulsed electromagnetic field frequencies on osteoarthritis. J Orthop Res. 2014 May;32(5):677-85
- Fini M et al. Razionale d'uso della stimolazione biofisica nell'algodistrofia. Chirurgia della Mano - Vol. 52 (3) 2015
- Veronesi F et al. Experimentally induced cartilage degeneration treated by pulsed electromagnetic field stimulation; an in vitro study on bovine cartilage. BMC Musculoskelet Disord. 2015 Oct 20;16(1):308
- Veronesi F et al. Pulsed electromagnetic fields combined with a collagenous scaffold and bone marrow concentrate enhance osteochondral regeneration: an in vivo study. BMC Musculoskelet Disord. 2015 Sep 2;16:233
- Massari L. La stimolazione biofisica articolare. Giornale Italiano di Ortopedia e Traumatologia. 2016;42(Suppl.1):S73-S78
- Servodio Iammarrone C et al. Is there a role of pulsed electromagnetic fields in management of patellofemoral pain syndrome? Randomized controlled study at one year follow-up. Bioelectromagnetics. 2016 Feb;37(2):81-8
- Massari L et al. Impiego clinico della stimolazione elettrica in ortopedia e traumatologia. Giornale Italiano di Ortopedia e Traumatologia. 2017;43:105-106
- Pagani S et al. Complex Regional Pain Syndrome Type I, a Debilitating and Poorly Understood Syndrome. Possible Role for Pulsed Electromagnetic Fields: A Narrative Review. Pain Physician. 2017 Sep;20(6):E807-E822
- Varani K et al. Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields," Mediators of Inflammation, vol. 2017, Article ID 2740963, 2017. doi:10.1155/2017/2740963

This folder refers to the medical device ref.CBA-03, Series I-ONE.
The device complies with the Medical Device Directive 93/42/EEC and its revised version. The device is marked CE 0051.
The device complies with the standard IEC 60601-1 - for the basic safety and essential performance of Medical electrical equipment.
The device complies with the standard IEC 60601-1-11 for the Medical electrical equipment used in the home healthcare environment.

IGEA/E012/06/21

IGEA Medical UK
Suites 1 & 2 Parkhill Business Park, Walton Road, Wetherby, West Yorkshire, LS22 5DZ | Phone: +44 1937 547065
www.igeamedical.com | info.uk@igeamedical.com